MedTrace Logo

Registry Platform Urologic Cancer

NCT03374267 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1930

Last updated 2025-09-22

No results posted yet for this study

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or urothelial cancer in Germany.

Conditions

Interventions

OTHER

Routine care as per site standard.

Physician's choice according to patient's needs.

Sponsors & Collaborators

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Michael Staehler, Prof. Dr. · Ludwig Maximilian University of Munich, Dept. of Urology - University Hospital, Munich, Germany

  • Peter Goebell, Prof. Dr. · University Clinic Erlangen, Department of Urology Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany

  • Lothar Müller, Dr. · Onkologie UnterEms, Leer-Emden-Papenburg, Leer, Germany

  • Viktor Grünwald, Prof. Dr. · University Hospital Essen West German Cancer Center Essen, Clinic for Medical Oncology and Clinic for Urology, Essen, Germany

  • Carsten Grüllich, Prof. Dr. · Sana Clinic Hof, Dept. of Hematology and Oncology, Hof, Germany

  • Christian Gratzke, Prof. Dr. · University Hospital Freiburg, Dept. of Urology, Freiburg, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-07
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Germany

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03374267 on ClinicalTrials.gov